mynth
← DATABASE
11/2021100%

Atos Medical acquired by Coloplast

SWEDEN Life Sciences / Medical Devices / Medical Consumables EV €1–10bn

Context

Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market. The rationale for the acquisition is highly strategic for Coloplast, as it adds a new chronic care segment to its existing portfolio. Atos Medical’s business model is a perfect fit for Coloplast’s "Chronic Care" strategy, characterized by high-recurring revenue from medical consumables and a strong direct-to-consumer orientation. The merger allows Coloplast to leverage Atos Medical’s industry-leading margins and unique patient-reach capabilities while providing Atos with Coloplast’s massive global infrastructure to further accelerate expansion in emerging and under-penetrated markets.

In the past, Atos Medical was acquired by PAI Partners in 2016 as part of its expansion strategy.

Atos Medical, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

Above 6x

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2021
€250–500M
[members only]
[members only]
2020
€250–500M
[members only]
[members only]

Other operations with Atos Medical

Other operations with Atos Medical
DateAcquirerTargetCountrySector
06/2016PAI PARTNERSATOS MEDICALSWEDENMedical Consumables

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
12/2021THE CARLYLE GROUP / GTCRRESONETICSUNITED STATESMedical Devices
12/2021INTEGEROSCORUNITED STATESImplants & Prosthetics
11/2021ESSLING CAPITAL / MULTICROISSANCE / BOURRELIER GROUPTEKNIMEDFRANCEImplants & Prosthetics
09/2021PERRIGO COMPANYHRA PHARMAFRANCEGenerics / Labs
07/2021PARTNERS GROUPPHARMATHENGREECECDMO
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
07/2021ORKLANUTRAQNORWAYNutrition & Dietary Supplements
04/2021NESTLETHE BOUNTIFUL COMPANYUNITED STATESNutrition & Dietary Supplements
04/2021DIASORINLUMINEX CORPORATIONUNITED STATESDiagnostic Equipment
04/2021NAXICAP PARTNERSLAGARRIGUEFRANCEImplants & Prosthetics

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €250–500M

EV/Revenue range: Above 6x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Atos Medical by Coloplast are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: atos medical

FAQ

What transaction does this page cover?

This page covers Coloplast’s acquisition of 100% of Atos Medical, a Swedish company specialised in Medical Devices, in 2021. This followed an earlier holding cycle initiated in June 2016, when the company was acquired by PAI Partners.

How was the acquisition of Atos Medical by Coloplast valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band and its EV/revenue multiple within the Above 6x range. Exact figures are available to members.

What was Atos Medical’s revenue at the time of the deal?

At the time of the transaction, Atos Medical’s annual revenue was estimated within the €250–500M range (FY 2021). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.